Higher 23,76 €	Lower 23,08 €
Open 23,1 €	Previous close 23,3 €
Volume78 863	Traded value 1 852 870,28 €
Capitalisation / nb of shares 792 295 780 € / 33 345 782	Capital turnover 0,24 %
Sector Industrie Pharmaceutique et Biotechnologie	main indices SBF 120, CAC ALL-TRADABLE
Market Euronext PARIS	Eligible (France): PEA SRD

Annonce

Stock price movement

06/02/2026 à 17:35:01

Technical analysis MEDINCELL

50-day moving average26,10 €	Pivot 23,53 €
Support 22,56 € -5.05 %	Résistance 29,20 € +22.90 %
1-month volatility 22,04 %	Annualized volatility 48,86 %
RSI (14d)Neutral (32)	Stochastic signal (14d) Achat
ATR (14d)Moderate volatility (0,99)	CMF (21d)Mildly bearish (-0,21)
Bollinger (20d)Neutral	OBV (21d) OBV data unavailable

Performance history

Since January 1st, the share price of MEDINCELL has fallen by -5,71%. Over three years, the stock has gained 212,60%. Over the past 12 months, MEDINCELL has recorded a decrease of -5.71%. In the medium term, the stock has shown a decline of -5.71% over the last three months. The share has been slightly volatile over the past rolling quarter. Considering the same periods, MEDINCELL has fluctuated by as much as % over the last three months and % over the past twelve months.

Please note: these indicators are for informational purposes only and do not guarantee future results. Past performance is not indicative of future performance.

Share price performance of MEDINCELL over various periods:

	Perf	Higher	Lower
1 week	+2,95%	23,76	22,3
1 month	-0,586%	29,30	22,3
3 months	-33,11%	36,00	22,3
6 months	+51,34%	39,68	15,61
12 months	+46,85%	39,68	12,00
3 years	+212,60%	39,68	5,25
5 years	+72,80%	39,68	4,73
Since IPO	+223,30%	39,68	4,35

The information provided in this document is for informational purposes only and should not be considered investment advice. Past performance is no guarantee of future returns. This product carries a risk of capital loss.

Relatited articles about MEDINCELL

News

31/01	Medincell's Stock Falls 21.5% Over the Week Despite Regulatory Progress
29/01	Medincell: European Filing Planned for Olanzapine LAI in Q2 2026
29/01	Medincell Shares Drop 2.91% in Late Afternoon Despite Stifel's Support
28/01	Medincell Drops 4.25% in Late Afternoon, Shares Lose Ground
27/01	Medincell Stock Rises 3.11% to €27.20 at Midday
26/01	Medincell Drops 8.56% in Session Despite Overbought RSI
17/01	MEDINCELL Stock: Shares Up 9.98% Over the Past Week
16/01	Medincell Stock Jumps 5% at Close Boosted by Oddo BHF
14/01	Medincell Advances 3.11% in Session Despite Limited Volumes
12/01	Medincell Announces Financial Calendar for 2026 and 2027
08/01	Medincell Stock Slightly Down at Close Amid Technical Pressure
12/12	Medincell's Stock Drops 3.91% by Midday this Friday, December 12
10/12	Medincell Shares Surge 6.95% Midday Following Two Strategic Announcements
10/12	Medincell's Stock Climbs 3.85% at Close Following Teva's Regulatory Filing with the FDA
09/12	Medincell Records a 50% Increase in Operating Income
09/12	Teva Pharmaceuticals Files Application with FDA for Olanzapine LAI
08/12	Medincell Stock Up 4.46% at Opening
27/11	MEDINCELL Shares Drop 3.64% at Close, Pausing After a Stellar Quarter
27/11	Medincell Participates in Conferences in December
24/11	Medincell Receives $3 Million Grant for Malaria Program

Industry data

Sector	CAC40 performance (%)	Euronext performance (%)

Health Care	-1.12%	-1.33%

Pharmaceuticals & Biotechnology	-0.90%	-1.45%

Biotechnology	N/A	-2.14%

Indice	Pts	Performance (%)

SBF 120	6261.75	+0.41%






NEXT BIOTECH	3412.88	+0.99%

SBF 120 data

Name	Price (€)	Perf.(%)
Best-performing stocks
Least-performing stocks

WARNINGS: The information presented here is based on data published by third-party information providers. It is not contractual and carries no guarantee of accuracy. It should not be considered as investment advice. Ideal-investisseur.fr cannot be held responsible for any potential damages or losses arising from the use of this information.

Stock MEDINCELL FR0004065605

Stock data: MEDINCELL